Literature DB >> 12411456

Treatment and control of hypertension in the community: a prospective analysis.

Donald M Lloyd-Jones1, Jane C Evans, Martin G Larson, Daniel Levy.   

Abstract

Cross-sectional national data indicate poor levels of treatment and control of hypertension. We identified factors that prospectively predict initiation of antihypertensive therapy and attainment of blood pressure control in the community. We included all Framingham Heart Study subjects examined between 1987 and 1999 who had untreated or uncontrolled hypertension (systolic > or =140 or diastolic > or =90 mm Hg) at a baseline examination and presented for follow-up examination 4 years later. Clinical covariates were examined for their association with initiation or control at follow-up. Among 1103 hypertensive participants who were untreated at baseline, 350 (31.7%) subjects were receiving therapy at follow-up, including 25.7% of subjects with stage 1 and 51.2% of those with stage > or =2 hypertension at baseline. Multivariate predictors of initiation of therapy included higher systolic and diastolic pressure, prevalent and interim cardiovascular disease, and left ventricular hypertrophy. Other cardiovascular risk factors did not predict initiation of treatment. Among 2475 hypertensive participants who were uncontrolled (treated or untreated) at baseline, 988 (39.9%) were controlled at follow-up. Prevalent cardiovascular disease and interim initiation of therapy predicted control; older age and higher baseline systolic levels predicted lack of control. These data provide estimates of longitudinal rates of treatment and control of hypertension in the community. It appears that global risk was not taken into consideration when making decisions for initiation of therapy. Greater emphasis is needed on achieving blood pressure control in all patients but particularly among older subjects and those with systolic hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411456     DOI: 10.1161/01.hyp.0000035855.44620.da

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  28 in total

1.  Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme.

Authors:  Daniel Pella
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-09-01

2.  Quantifying cardiometabolic risk using modifiable non-self-reported risk factors.

Authors:  Miguel Marino; Yi Li; Michael J Pencina; Ralph B D'Agostino; Lisa F Berkman; Orfeu M Buxton
Journal:  Am J Prev Med       Date:  2014-06-17       Impact factor: 5.043

3.  Neurocognition in treatment-resistant hypertension: profile and associations with cardiovascular biomarkers.

Authors:  Patrick J Smith; James A Blumenthal; Alan L Hinderliter; Stephanie M Mabe; Jeanne E Schwartz; Forgive Avorgbedor; Andrew Sherwood
Journal:  J Hypertens       Date:  2019-05       Impact factor: 4.844

4.  Left ventricular hypertrophy by electrocardiogram as a predictor of success in home blood pressure control: HOMED-BP study.

Authors:  Ayumi Tanabe; Kei Asayama; Tomohiro Hanazawa; Daisuke Watabe; Kyoko Nomura; Tomonori Okamura; Takayoshi Ohkubo; Yutaka Imai
Journal:  Hypertens Res       Date:  2017-01-12       Impact factor: 3.872

Review 5.  Moving beyond guidelines: are report cards the answer to high rates of uncontrolled hypertension?

Authors:  Marcel Ruzicka; Frans H H Leenen
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

6.  [Fundus hypertonicus Okulare Veranderungen bei systemischen Erkrankungen].

Authors:  U E K Schnurrbusch; S Wolf
Journal:  Ophthalmologe       Date:  2005-03       Impact factor: 1.059

Review 7.  Drospirenone for oral contraception and hormone replacement therapy: are its cardiovascular risks and benefits the same as other progestogens?

Authors:  Apurva Motivala; Bertram Pitt
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  Efficacy and safety of triple antihypertensive therapy with the olmesartan/amlodipine/hydrochlorothiazide combination.

Authors:  Massimo Volpe; Lars Christian Rump; Bettina Ammentorp; Petra Laeis
Journal:  Clin Drug Investig       Date:  2012-10-01       Impact factor: 2.859

9.  Cost sharing and the initiation of drug therapy for the chronically ill.

Authors:  Matthew D Solomon; Dana P Goldman; Geoffrey F Joyce; José J Escarce
Journal:  Arch Intern Med       Date:  2009-04-27

10.  Prevalence, awareness, treatment, and control of hypertension: United States National Health and Nutrition Examination Survey 2001-2002.

Authors:  Bernard M Y Cheung; Kwok Leung Ong; Yu Bun Man; Karen S L Lam; Chu-Pak Lau
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-02       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.